The rewarding and locomotor-sensitizing effects of repeated cocaine administration are distinct and separable in mice. Academic Article uri icon

Overview

abstract

  • Repeated psychostimulant exposure progressively increases their potency to stimulate motor activity in rodents. This behavioral or locomotor sensitization is considered a model for some aspects of drug addiction in humans, particularly drug craving during abstinence. However, the role of increased motor behavior in drug reward remains incompletely understood. Intracranial self-stimulation (ICSS) was measured concurrently with locomotor activity to determine if acute intermittent cocaine administration had distinguishable effects on motor behavior and perception of brain stimulation-reward (BSR) in the same mice. Sensitization is associated with changes in neuronal activity and glutamatergic neurotransmission in brain reward circuitry. Expression of AMPA receptor subunits (GluR1 and GluR2) and CRE binding protein (CREB) was measured in the ventral tegmental area (VTA), dorsolateral striatum (STR) and nucleus accumbens (NAc) before and after a sensitizing regimen of cocaine, with and without ICSS. Repeated cocaine administration sensitized mice to its locomotor-stimulating effects but not its ability to potentiate BSR. ICSS increased GluR1 in the VTA but not NAc or STR, demonstrating selective changes in protein expression with electrical stimulation of discrete brain structures. Repeated cocaine reduced GluR1, GluR2 and CREB expression in the NAc, and reductions of GluR1 and GluR2 but not CREB were further enhanced by ICSS. These data suggest that the effects of repeated cocaine exposure on reward and motor processes are dissociable in mice, and that reduction of excitatory neurotransmission in the NAc may predict altered motor function independently from changes in reward perception.

publication date

  • December 16, 2011

Research

keywords

  • Behavior, Animal
  • Cocaine
  • Dopamine Uptake Inhibitors
  • Motor Activity
  • Reward

Identity

PubMed Central ID

  • PMC3269519

Scopus Document Identifier

  • 84856428422

Digital Object Identifier (DOI)

  • 10.1016/j.neuropharm.2011.12.011

PubMed ID

  • 22197517

Additional Document Info

volume

  • 62

issue

  • 4